Zhengchuan Shares released its 2026 interim report on the evening of August 28. During the reporting period, the company achieved operating revenue of 381 million yuan, up 17.58 percent year on year. Net profit attributable to the parent company was 12.2866 million yuan, down 12.79 percent year on year. Net cash flow from operating activities was 79.3259 million yuan, up 33.63 percent year on year. The company said that in the first half it actively stepped up market development, with both product sales volume and operating revenue scale achieving year-on-year growth. Facing a complex and severe external environment and the pains of industry transformation, the company consolidated its core business in traditional chemical pharmaceutical packaging while focusing on three emerging tracks: innovative drug supporting packaging, premium medical aesthetics packaging, and overseas international trade. The company seized industry opportunities from the commercialization ramp-up of innovative drugs, the expansion of the biologics market, and the rapid growth of the medical aesthetics injectables market. It continued to advance a more premium and differentiated product mix, with a key push into high-tech, high-value-added premium pharmaceutical glass products such as prefillable syringes, cartridge bottles, and ready-to-use molded vials. In the traditional business segment, market demand in the oral liquid pharmaceutical packaging materials sector remained steady, supply and demand for chemical pharmaceutical glass tubing continued to improve, and product volumes and prices gradually recovered. In the premium business segment, the company has completed product sampling, process validation, and small-batch supply for multiple well-known enterprises. In the medical aesthetics packaging segment, the company focused on mid-to-high-end, high-value-added product positioning, with operating results gradually being released. In the overseas business segment, the export share of high-value-added products steadily increased.
ChongQing Zhengchuan Pharmaceutical Packaging Co LtdRevenue growth driven by increased product sales and market development, with premium product mix advancing.
